Motrin, tablets 250 mg 10 pcs

Pain after injuries and operations, Arthritis, Flu, Arthrosis, Back pain, Pain, Sciatica, Neck pain, Lumbago, Osteoarthritis, Headache, Neuralgia (nerve pain), Migraine, Toothache, Angina, Myalgia (muscle pain), Sore throat, Menstrual pain (algodysmenorrhea), Joint pain (arthralgia), Muscle pain (myalgia), Infectious diseasesMild to moderate pain syndrome: Neuralgia, ossalgia, myalgia, lumbo-ischialgia, post-traumatic pain syndrome (sprains and contusions) accompanied by inflammation, postoperative pain (in trauma, orthopedics, gynecology, maxillofacial surgery), headache, migraine, algodysmenorrhea, adnexitis, toothache.

Symptomatic pain therapy in diseases of the musculoskeletal system, including bursitis, tendovaginitis.

In combination therapy of infectious and inflammatory diseases of the ear, throat and nose with a pronounced pain syndrome (pharyngitis, tonsillitis, otitis).

Feverish conditions with flu and colds.

The drug is used for symptomatic therapy (to reduce pain, inflammation and elevated body temperature) and has no effect on the progression of the main disease.

Indications

Pain syndrome of mild and moderate severity: neuralgia, ossalgia, myalgia, lumboischialgia, post-traumatic pain syndrome (sprains and bruises), accompanied by inflammation, postoperative pain (in traumatology, orthopedics, gynecology, maxillofacial surgery), headache, migraine, algodismenorrhea, adnexitis, toothache.

Symptomatic treatment of pain in diseases of the musculoskeletal system, including bursitis, tendovaginitis.

As part of complex therapy for infectious and inflammatory diseases of the ear, nose and throat with severe pain (pharyngitis, tonsillitis, otitis).

Fever due to influenza and colds.

The drug is used for symptomatic therapy (to reduce pain, inflammation and fever) and does not affect the progression of the underlying disease.

Special instructions

Do not exceed the doses specified in the instructions. To reduce the risk of developing adverse events from the gastrointestinal tract, the minimum effective dose should be used for the shortest possible course. If pain and fever persist or get worse, you should see a doctor.

Patients with bronchial asthma, bleeding disorders, and patients with hypersensitivity to other analgesics should consult a doctor before taking naproxen.

Caution should be used in patients with liver disease and renal failure. In patients with renal failure, creatinine clearance should be monitored. In chronic alcoholism and other forms of liver cirrhosis, the concentration of unbound naproxen increases, so lower doses are recommended for such patients.

Naproxen should not be taken with other anti-inflammatory or pain relievers unless directed by a doctor. Lower doses are also recommended for elderly patients. Naproxen should be avoided within 48 hours before surgery. If it is necessary to determine 17 corticosteroids, the drug should be discontinued 48 hours before the study. Likewise, naproxen may interfere with the determination of 5-hydroxyindoleacetic acid in urine. The use of naproxen, like other drugs that block prostaglandin synthesis, may affect fertility and is therefore not recommended for women planning pregnancy.

Active ingredient

Naproxen

Composition

One tablet contains:

active substance:

naproxen in terms of 100% substance – 250.00 mg;

excipients:

lactose monohydrate – 71.12 mg,

potato starch – 42.00 mg,

povidone – 16.00 mg,

magnesium stearate – 0.76 mg,

dye tropeolin O – 0.12 mg.

Contraindications

Hypersensitivity to naproxen or naproxen sodium; complete or incomplete combination of bronchial asthma, recurrent polyposis of the nose and paranasal sinuses and intolerance to acetylsalicylic acid or other non-steroidal anti-inflammatory drugs (including a history). During the period of coronary artery bypass surgery.

Erosive and ulcerative lesions of the stomach and duodenum in the acute phase (ulcerative colitis (UC), Crohn’s disease).

Cerebrovascular bleeding or other bleeding and hemostasis disorders.

Severe renal failure (creatinine clearance less than 30 ml/min), incl. confirmed hyperkalemia, progressive kidney disease.

Inhibition of bone marrow hematopoiesis.

Pregnancy, breastfeeding period.

Children’s age up to 12 years.

Side Effects

Side effects are most common when using high doses of the drug:

– from the digestive system: constipation, abdominal pain, dyspepsia, nausea, diarrhea, ulcerative stomatitis, erosive and ulcerative lesions and bleeding of the gastrointestinal tract, NSAID gastropathy (damage to the antrum of the stomach in the form of erythema of the mucous membrane, hemorrhages, erosions and ulcers), increased activity of liver enzymes, impaired liver function, jaundice, bloody vomiting, melena;

– from the central nervous system: hearing loss, dizziness, headache, drowsiness, depression, sleep disturbances, inability to concentrate, insomnia, malaise, slow psychomotor reactions, aseptic meningitis, cognitive dysfunction;

– from the skin: itching, ecchymosis, increased sweating, purpura, alopecia, photodermatosis;

– from the senses: tinnitus, visual impairment, hearing impairment;

– from the cardiovascular system: swelling of the face, limbs, shortness of breath, palpitations, the emergence or worsening of existing chronic heart failure, vasculitis;

– from the genitourinary system: glomerulonephritis, hematuria, interstitial nephritis, nephrotic syndrome, renal failure, renal papillary necrosis, menstrual irregularities;

– from the hematopoietic organs: eosinophilia, granulocytopenia, leukopenia, thrombocytopenia, aplastic anemia, hemolytic anemia;

– from the respiratory system: eosinophilic pneumonitis;

– allergic reactions: skin rash, urticaria, angioedema, toxic epidermal necrolysis, erythema multiforme, Stevens-Johnson syndrome;

– others: thirst, hyperthermia, hyperglycemia, hypoglycemia, myalgia and muscle weakness.

Interaction

When treating with anticoagulants, be aware that naproxen may prolong bleeding time.

The drug should not be used simultaneously with other NSAIDs (increased risk of side effects).

When used simultaneously with hydantoin derivatives, anticoagulants or other drugs that bind significantly to plasma proteins, the effect of these drugs may be potentiated.

Naproxen may reduce the antihypertensive effects of propranolol and other beta blockers and may increase the risk of renal failure associated with ACE inhibitor use.

Naproxen inhibits the natriuretic effect of furosemide. Inhibition of renal clearance of lithium results in increased plasma lithium concentrations.

Taking probenecid increases plasma concentrations of naproxen.

Cyclosporine increases the risk of developing renal failure.

Naproxen slows down the excretion of methotrexate, phenytoin, and sulfonamides, increasing the risk of developing their toxic effects.

Antacids containing magnesium and aluminum reduce the absorption of naproxen.

Overdose

A significant overdose of the drug can be characterized by drowsiness, dyspeptic disorders (heartburn, nausea and vomiting, abdominal pain), weakness, tinnitus, irritability, and in severe cases, hematemesis, melena, impaired consciousness, convulsions and renal failure.

Treatment: gastric lavage, taking activated charcoal and carrying out symptomatic therapy: antacids, H2-histamine receptor blockers, proton pump inhibitors. Hemodialysis is ineffective.

Clinical pharmacology

Pharmacodynamics: Non-steroidal anti-inflammatory drug (NSAID), has anti-inflammatory, analgesic and antipyretic effects associated with non-selective suppression of the activity of cyclooxygenase 1 and cyclooxygenase 2, which regulate the synthesis of prostaglandins.

Pharmacokinetics:

Absorption from the gastrointestinal tract is fast and complete, bioavailability is 95% (food intake has virtually no effect on either the completeness or the rate of absorption). Time to reach maximum concentration (TCmax) – 2 hours, binding to plasma proteins – 99%, half-life (T1/2) – 12-15 hours.

Metabolism – in the liver to dimethylnaproxen with the participation of the CYP2C9 enzyme system. Clearance – 0.13 ml/min/kg.

98% is excreted by the kidneys, 10% of which is excreted unchanged; with bile – 0.5-2.5%. The equilibrium concentration of the drug in the blood plasma (Css) is determined after 2-3 days. In chronic renal failure, accumulation of metabolites is possible.

Short product description

Has an analgesic effect, remaining in the body for up to 12-15 hours 1.

1-Frickle et al. Efficacy and safety of naproxen sodium and ibuprofen for pain relief after oral surgery. Current Therapeutic Research. 1993;54(6):619-27.

Storage conditions

In a dry place, protected from light, at a temperature not exceeding 25 ºС. Keep out of the reach of children.

Shelf life

3 years.

Manufacturer

Akrikhin JSC, Russia